Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Head & Neck 3Dermatologic 3Thoracic 2Gynecologic 2Genitourinary 2Breast 2Sarcoma 1

Conditions

Ovarian Neoplasms 8Uterine Cervical Neoplasms 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Neoplasms 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Prostatic Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Thyroid Neoplasms 1Skin Neoplasms 1Sarcoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

pembrolizumab 8Oxaliplatin 7Surveys and Questionnaires 5Methods 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Gemcitabine 4Fluorouracil 4Carboplatin 4veliparib 3aldesleukin 3Trastuzumab 3Specimen Handling 3Nivolumab 3Diathermy 3Cytoreduction Surgical Procedures 3sargramostim 2entinostat 2cemiplimab 2cediranib 2X-Rays 2Therapeutics 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × cemiplimab × Gynecologic × Clear all
NCT05259696 2025-08-20

GLIMMER-01

Palleon Pharmaceuticals, Inc.

Phase 1/2 Completed
69 enrolled 13 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Sensei Biotherapeutics, Inc.

Phase 1/2 Active not recruiting
98 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡